For patients with and without type 2 diabetes, GLP-1 receptor agonist and/or SGLT2i therapy is recommended for individuals with a high risk of developing ASCVD; and to reduce progression to chronic kidney disease (CKD). The gene discussed is GLP1R; the disease is chronic kidney disease.